Royalty Pharma plc
RPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $16 | $13 | $11 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $9 | $8 | $8 | $8 |
| Enterprise Value | – | $23 | $20 | $18 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 5.3% | 1.8% | -4.3% | – |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 86.2% | 27.5% | 87.8% | 67.4% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 47.3% | 5.2% | 41.9% | 35.1% |
| EPS Diluted | 0.67 | 0.071 | 0.41 | 0.35 |
| % Growth | 845% | -82.7% | 17.1% | – |
| Operating Cash Flow | $1 | $0 | $1 | $1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $1 | $0 | $1 | $1 |